Retinal Amyloid Imaging for Screening Alzheimer's Disease

Koh Tadokoro, Toru Yamashita, Shuhei Kimura, Emi Nomura, Yasuyuki Ohta, Yoshio Omote, Mami Takemoto, Nozomi Hishikawa, Ryuta Morihara, Yuki Morizane, Koji Abe, Kenjiro Ono

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Background: Cost-effective and noninvasive methods for in vivo imaging of amyloid deposition are needed to screen Alzheimer's disease (AD). Although retinal amyloid is a possible diagnostic marker of AD, there are very few studies on in vivo retinal amyloid imaging. Objective: To examine the usefulness of in vivo imaging of retinal amyloid in AD patients. Methods: To examine amyloid deposition, 30 Japanese subjects (10 normal control (NC), 7 with mild cognitive impairment (MCI), and 13 with AD) underwent a complete ophthalmic examination, including fundus imaging by scanning laser ophthalmoscopy before and after oral curcumin intake. Results: Retinal amyloid deposition was greater in AD than in NC subjects (∗p<0.05) while MCI showed a slight but insignificant increase of retinal amyloid deposition relative to NC subjects. Retinal amyloid deposition was correlated with whole gray matter atrophy (r=0.51, ∗p<0.05) but not with the cognitive score of the Mini-Mental State Examination, nor with medial temporal lobe atrophy. Conclusion: The present noninvasive in vivo detection of retinal amyloid deposition is useful for screening AD patients.

Original languageEnglish
Pages (from-to)927-934
Number of pages8
JournalJournal of Alzheimer's Disease
Issue number2
Publication statusPublished - 2021


  • Alzheimer's disease
  • amyloid
  • mild cognitive impairment
  • retina

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Retinal Amyloid Imaging for Screening Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this